Cancer Drug Development Using Drosophila as an in vivo Tool: From Bedside to Bench and Back.

The fruit fly Drosophila melanogaster has been used for modeling cancer and as an in vivo tool for the validation and/or development of cancer therapeutics. The impetus for the use of Drosophila in cancer research stems from the high conservation of its signaling pathways, lower genetic redundancy, short life cycle, genetic amenability, and ease of maintenance. Several cell signaling pathways in Drosophila have been used for cancer drug development. The efficacy of combination therapy and uptake/bioavailability of drugs have also been studied. Drosophila has been validated using several FDA-approved drugs, suggesting a potential application of this model in drug repurposing. The model is emerging as a powerful tool for high-throughput screening and should significantly reduce the cost and time associated with drug development. In this review we discuss the applications of Drosophila in cancer drug development. The advantages and limitations of the model are discussed.

[1]  E. Petricoin,et al.  Drosophila screening model for metastasis: Semaphorin 5c is required for l(2)gl cancer phenotype , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  O. Sibon,et al.  Contribution of Growth and Cell Cycle Checkpoints to Radiation Survival in Drosophila , 2006, Genetics.

[3]  M. B. Stark.  An Hereditary Tumor in the Fruit Fly, Drosophila , 1918 .

[4]  A. Efrat,et al.  Phenotypes of Drosophila Brain Neurons in Primary Culture Reveal a Role for Fascin in Neurite Shape and Trajectory , 2006, The Journal of Neuroscience.

[5]  Stephen Brown,et al.  Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasms , 2015, The Lancet.

[6]  J. Delcros,et al.  A Drosophila model to identify polyamine-drug conjugates that target the polyamine transporter in an intact epithelium. , 2008, Journal of medicinal chemistry.

[7]  L. Tanoue.  Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .

[8]  Jon R. Armstrong,et al.  A Drosophila Model of Multiple Endocrine Neoplasia Type 2 , 2005, Genetics.

[9]  J. Egly,et al.  TFIIH: when transcription met DNA repair , 2012, Nature Reviews Molecular Cell Biology.

[10]  D. Backos,et al.  Strategies and Approaches of Targeting STAT3 for Cancer Treatment. , 2016, ACS chemical biology.

[11]  T. Ciuleanu,et al.  Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. , 2012, The Lancet. Oncology.

[12]  T. Golde,et al.  Rational targeting of Notch signaling in cancer , 2008, Oncogene.

[13]  Tiefen Su,et al.  Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer , 2016, Oncotarget.

[14]  D. Raben,et al.  Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells , 2011, Disease Models & Mechanisms.

[15]  Lili Wang,et al.  Regulation of the phosphorylation and nuclear import and export of &bgr;-catenin by APC and its cancer-related truncated form , 2014, Journal of Cell Science.

[16]  Jiang Xu,et al.  The role of XPD in cell apoptosis and viability and its relationship with p53 and cdk2 in hepatoma cells , 2012, Medical Oncology.

[17]  N. Perrimon,et al.  In Vivo Transcriptional Activation Using CRISPR/Cas9 in Drosophila , 2015, Genetics.

[18]  Sahdeo Prasad,et al.  Cancer drug discovery by repurposing: teaching new tricks to old dogs. , 2013, Trends in pharmacological sciences.

[19]  J. Christensen,et al.  Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. , 2011, The Biochemical journal.

[20]  M. Zurita,et al.  The genetic depletion or the triptolide inhibition of TFIIH in p53-deficient cells induces a JNK-dependent cell death in Drosophila , 2013, Journal of Cell Science.

[21]  B. Levine,et al.  Drosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate Therapeutic. , 2016, Cell reports.

[22]  D. Raben,et al.  A translation inhibitor identified in a Drosophila screen enhances the effect of ionizing radiation and taxol in mammalian models of cancer , 2012, Disease Models & Mechanisms.

[23]  Hao Yin,et al.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.

[24]  D. Pfister,et al.  Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Miki,et al.  A genetic screen in Drosophila for regulators of human prostate cancer progression. , 2014, Biochemical and biophysical research communications.

[26]  G. Fontanini,et al.  ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. , 2002, Cancer research.

[27]  A. Bosserhoff,et al.  Reduced expression of Hugl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer , 2005, Oncogene.

[28]  Kevan M. Shokat,et al.  Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.

[29]  S. Lele,et al.  YAP regulates cell proliferation, migration, and steroidogenesis in adult granulosa cell tumors. , 2014, Endocrine-related cancer.

[30]  D. Brat,et al.  Drosophila Brat and Human Ortholog TRIM3 Maintain Stem Cell Equilibrium and Suppress Brain Tumorigenesis by Attenuating Notch Nuclear Transport. , 2016, Cancer research.

[31]  G M Rubin,et al.  A screen for genes that function downstream of Ras1 during Drosophila eye development. , 1996, Genetics.

[32]  S. Roman,et al.  Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer , 2011, Clinical Medicine Insights. Oncology.

[33]  Webster K. Cavenee,et al.  A Drosophila Model for EGFR-Ras and PI3K-Dependent Human Glioma , 2009, PLoS genetics.

[34]  D. Hultmark,et al.  JAK/STAT signaling in Drosophila muscles controls the cellular immune response against parasitoid infection , 2015, EMBO reports.

[35]  Sourajit Das,et al.  Artemisinin and Curcumin inhibit Drosophila brain tumor, prolong life span, and restore locomotor activity , 2014, IUBMB life.

[36]  R. Dasgupta,et al.  An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway , 2011, Proceedings of the National Academy of Sciences.

[37]  Michele Markstein.  Modeling colorectal cancer as a 3-dimensional disease in a dish: the case for drug screening using organoids, zebrafish, and fruit flies. , 2013, Drug discovery today. Technologies.

[38]  Marianne Malartre.  Regulatory mechanisms of EGFR signalling during Drosophila eye development , 2016, Cellular and Molecular Life Sciences.

[39]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[40]  P. Bhandari,et al.  Studies on human colon cancer gene APC by targeted expression in Drosophila , 2001, Oncogene.

[41]  Norbert Perrimon,et al.  Signaling mechanisms controlling cell fate and embryonic patterning. , 2012, Cold Spring Harbor perspectives in biology.

[42]  B. Aggarwal,et al.  Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials , 2012, The AAPS Journal.

[43]  A. Kassam,et al.  Inhibition of glioblastoma malignancy by Lgl1 , 2014, Oncotarget.

[44]  S. Artavanis-Tsakonas,et al.  Notch Signaling : Cell Fate Control and Signal Integration in Development , 1999 .

[45]  P. Sun,et al.  TSC1/2 tumour suppressor complex maintains Drosophila germline stem cells by preventing differentiation , 2010, Development.

[46]  E. Gerner,et al.  Targeting polyamines and inflammation for cancer prevention. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[47]  Sudhir Kumar,et al.  Comparative Genomics in Eukaryotes , 2005 .

[48]  C. Bryant,et al.  Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer , 2009, Pharmacological Reviews.

[49]  Steven E Schild,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[50]  B. Aggarwal,et al.  Signal Transducer and Activator of Transcription‐3, Inflammation, and Cancer , 2009, Annals of the New York Academy of Sciences.

[51]  R. Cagan,et al.  A Drosophila approach to thyroid cancer therapeutics. , 2013, Drug discovery today. Technologies.

[52]  J. Bryan,et al.  Fascin, an echinoid actin-bundling protein, is a homolog of the Drosophila singed gene product. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Timothy K Lu,et al.  Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM , 2016, Proceedings of the National Academy of Sciences.

[54]  Mark Bathe,et al.  Structure, evolutionary conservation, and conformational dynamics of Homo sapiens fascin-1, an F-actin crosslinking protein. , 2010, Journal of molecular biology.

[55]  Olivier Elemento,et al.  DrugTargetSeqR: a genomics- and CRISPR/Cas9-based method to analyze drug targets , 2014, Nature chemical biology.

[56]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[57]  C. Klämbt,et al.  ECM stiffness regulates glial migration in Drosophila and mammalian glioma models , 2014, Development.

[58]  D. Krantz,et al.  Transport of polyamines in Drosophila S2 cells: kinetics, pharmacology and dependence on the plasma membrane proton gradient. , 2006, The Biochemical journal.

[59]  R. Steward,et al.  Nuclear factor-kappa B pathways in Drosophila , 2006, Oncogene.

[60]  William R. Sellers,et al.  Advances in the preclinical testing of cancer therapeutic hypotheses , 2011, Nature Reviews Drug Discovery.

[61]  J. C. Pastor-Pareja,et al.  Basement membrane remodeling is essential for Drosophila disc eversion and tumor invasion , 2007, Proceedings of the National Academy of Sciences.

[62]  Tian Xu,et al.  A Genetic Screen in Drosophila for Metastatic Behavior , 2003, Science.

[63]  J. Nitiss.  Targeting DNA topoisomerase II in cancer chemotherapy , 2009, Nature Reviews Cancer.

[64]  E. Prochownik,et al.  Permanently Blocked Stem Cells Derived From Breast Cancer Cell Lines , 2010, Stem cells.

[65]  K. Garber.  ALK, lung cancer, and personalized therapy: portent of the future? , 2010, Journal of the National Cancer Institute.

[66]  B. Aggarwal,et al.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy. , 2010, Biochimica et biophysica acta.

[67]  H. Richardson,et al.  Using Drosophila melanogaster to map human cancer pathways , 2005, Nature Reviews Cancer.

[68]  Adam A. Friedman,et al.  A functional RNAi screen for regulators of receptor tyrosine kinase and ERK signalling , 2006, Nature.

[69]  D. Brat,et al.  Anti-Invasive Adjuvant Therapy with Imipramine Blue Enhances Chemotherapeutic Efficacy Against Glioma , 2012, Science Translational Medicine.

[70]  H. Richardson,et al.  An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery , 2012, Disease Models & Mechanisms.

[71]  Y. Yen,et al.  γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers , 2012, PloS one.

[72]  N. Perrimon,et al.  Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. , 1995, The EMBO journal.

[73]  R. Palmer,et al.  Crizotinib--latest champion in the cancer wars? , 2010, The New England journal of medicine.

[74]  A. Ramasamy,et al.  Drosophila-based in vivo assay for the validation of inhibitors of the epidermal growth factor receptor/Ras pathway , 2008, Journal of Biosciences.

[75]  Frank Speleman,et al.  Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification , 2010, Clinical Cancer Research.

[76]  Jun O. Liu,et al.  XPB, a subunit of TFIIH, is a target of the natural product triptolide. , 2011, Nature chemical biology.

[77]  M. Fortini,et al.  Ca2+‐ATPase function is required for intracellular trafficking of the Notch receptor in Drosophila , 1999, The EMBO journal.

[78]  B. Aggarwal,et al.  Role of nuclear factor-κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents , 2011, Experimental biology and medicine.

[79]  Patrick Schultz,et al.  Structural insight into negative DNA supercoiling by DNA gyrase, a bacterial type 2A DNA topoisomerase , 2013, Nucleic acids research.

[80]  B. Dickson,et al.  The Drosophila Tuberous Sclerosis Complex Gene Homologs Restrict Cell Growth and Cell Proliferation , 2001, Cell.

[81]  C. Bailly,et al.  An Integrated Drosophila Model System Reveals Unique Properties for F14512, a Novel Polyamine-Containing Anticancer Drug That Targets Topoisomerase II , 2011, PloS one.

[82]  P. Polakis.  The many ways of Wnt in cancer. , 2007, Current opinion in genetics & development.

[83]  N. Perrimon,et al.  Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. , 2013, Cancer cell.

[84]  K. Kinzler,et al.  Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. , 1991, Science.

[85]  M. Zurita,et al.  DNA repair and transcriptional effects of mutations in TFIIH in Drosophila development. , 2002, Molecular biology of the cell.

[86]  T. Magnaldo,et al.  Nucleotide excision repair and related human diseases. , 2006, Genome dynamics.

[87]  Aik Choon Tan,et al.  Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.

[88]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[89]  X. Thuru,et al.  Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma , 2015, Clinical Cancer Research.

[90]  Hans Clevers,et al.  Mining the Wnt pathway for cancer therapeutics , 2007, Nature Reviews Drug Discovery.

[91]  Byung Hak Kim,et al.  A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells , 2008, Molecular Cancer Therapeutics.

[92]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[93]  M. Milner,et al.  The ultrastructure of imaginal disc cells in primary cultures and during cell aggregation in continuous cell lines. , 1990, Tissue & cell.

[94]  A. Ryan,et al.  ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. , 2005, Cancer research.

[95]  Hans Clevers,et al.  Mining the Wnt pathway for cancer therapeutics , 2006, Nature Reviews Drug Discovery.

[96]  Ethan Bier,et al.  Drosophila, the golden bug, emerges as a tool for human genetics , 2005, Nature Reviews Genetics.

[97]  M. Wei,et al.  Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug , 2011, Journal of biomedicine & biotechnology.

[98]  P. Natali,et al.  Understanding Human Cancer Using Drosophila , 2003, Journal of Biological Chemistry.

[99]  M. Hild,et al.  In vivo analysis of compound activity and mechanism of action using epistasis in Drosophila , 2011, Journal of chemical biology.

[100]  José L. Medina-Franco,et al.  A cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functions , 2013, Journal of Cell Science.

[101]  T. T. Su,et al.  Summary Background: Components of the DNA damage check- , 2022 .

[102]  A. Simcox,et al.  Dpp-induced Egfr signaling triggers postembryonic wing development in Drosophila , 2013, Proceedings of the National Academy of Sciences.

[103]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[104]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[105]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[106]  E. Batlle,et al.  Conserved Mechanisms of Tumorigenesis in the Drosophila Adult Midgut , 2014, PloS one.

[107]  W F Bodmer,et al.  The ABC of APC. , 2001, Human molecular genetics.

[108]  H. Carén,et al.  Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. , 2011, Cancer research.

[109]  L. Machesky,et al.  Fascin: Invasive filopodia promoting metastasis. , 2010, Communicative & integrative biology.

[110]  R. Palmer,et al.  Anaplastic lymphoma kinase: signalling in development and disease , 2009, The Biochemical journal.

[111]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[112]  I. Lax,et al.  Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions , 2015, Proceedings of the National Academy of Sciences.

[113]  Vladimir Torchilin,et al.  Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance , 2012, Clinical Cancer Research.

[114]  H. Richardson,et al.  scribble mutants cooperate with oncogenic Ras or Notch to cause neoplastic overgrowth in Drosophila , 2003, The EMBO journal.

[115]  N. Perrimon,et al.  Systematic screen of chemotherapeutics in Drosophila stem cell tumors , 2014, Proceedings of the National Academy of Sciences.